Literature DB >> 17785012

Papulonecrotic tuberculid in an HIV-positive patient.

Victoria Akhras1, Gill McCarthy.   

Abstract

We present a 33-year-old HIV-positive man who presented with a two-year history of a non-itchy papular eruption, associated with night sweats, headaches, poor memory and weight loss. On examination, he had erythematous papular lesions with necrotic centres on the face, arms and torso with no systemic abnormalities. A skin biopsy eventually led to the diagnosis of papulonecrotic tuberculid, and treatment with quadruple therapy resulted in resolution of his rash and systemic symptoms. Papulonecrotic tuberculid is thought to be a immunological response to Mycobacterium bacillus components in a previously sensitized patient following haematogenous spread from a focus of infection elsewhere. Cultures from the skin are typically negative and there are no acid-fast bacilli seen, but mycobacterial DNA can be detected using polymerase chain reaction. This case is an example of the paradoxical activation of the immune system seen in patients with HIV. It highlights the importance of skin biopsy in patients with unexplained systemic symptoms and a rash, as the differential diagnosis can be wide in HIV.

Entities:  

Mesh:

Year:  2007        PMID: 17785012     DOI: 10.1258/095646207781568628

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Papulonecrotic tuberculid-clinicopathologic and molecular features of 12 Indian patients.

Authors:  Rajalakshmi Tirumalae; Inchara K Yeliur; Meryl Antony; Geojith George; John Kenneth
Journal:  Dermatol Pract Concept       Date:  2014-04-30

2.  Cutaneous tuberculosis and HIV infection at a referral centre in Rio de Janeiro, Brazil.

Authors:  Danielle Mann; Flávia Marinho Sant'Anna; Carolina Arana Stanis Schmaltz; Dayvison Francis Saraiva Freitas; Valeria Cavalcanti Rolla; Solange Cesar Cavalcante; Maria Clara Gutierrez-Galhardo
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-07-26       Impact factor: 2.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.